Background: Treatment of preoperative anaemia is recommended as part of patient blood management, aiming to minimize perioperative allogeneic red blood cell transfusion. No clear evidence exists outlining which treatment modality should be used in patients with colorectal cancer. The study aimed to compare the efficacy of preoperative intravenous and oral iron in reducing blood transfusion use in anaemic patients undergoing elective colorectal cancer surgery.
Introduction
Patient blood management is a concept that is increasingly advocated in the management of surgical patients. The ultimate aim is to improve patient outcomes by reducing the use of allogeneic red blood cell transfusion except in scenarios of absolute need 1 . The rationale for avoiding perioperative allogeneic blood transfusion stems from the associated risks. Aside from the expense, relative scarcity and recognized infective, immunological and biochemical complications associated with blood transfusion 2 , growing evidence suggests it impairs postoperative outcome in both the short and long term. In the specific context of colorectal cancer surgery, two large meta-analyses 3, 4 have highlighted the concern that perioperative blood transfusion may be associated with increased postoperative infection rates, length of hospital stay, mortality 3 and cancer recurrence 3, 4 . The mechanism behind this association may relate to the immunomodulatory effects of blood transfusion, as immune mediators in stored blood may cause a 'protumour' state 5 . As surgery has been linked with detrimental alterations to immune function, predisposing to infection and cancer recurrence 6 , addition of the potential risks from perioperative blood transfusion should be avoided. Supporting this mechanism, observational data have shown a dose-dependent correlation between the number of units of blood administered and complication rates following major gastrointestinal surgery 7 and non-cardiac surgery 8 .
One key area of focus in patient blood management is the early identification and treatment of pre-existing anaemia 1 . This is of particular relevance in the context of colorectal malignancy, where the prevalence of anaemia at diagnosis is up to 40 per cent 9 . Anaemia itself has been proposed as an independent risk factor for adverse outcome following colorectal cancer surgery 10 . This is most frequently iron-deficient in aetiology 11 , so early treatment of anaemia with iron supplementation has been proposed as a feasible technique to minimize blood transfusion requirement in patients having colorectal cancer surgery 12 . Recent meta-analyses 13, 14 investigating the role of iron supplementation in the preoperative optimization of anaemic surgical patients have been unsuccessful owing to a paucity of data. Consequently, the need for a randomized trial to compare the efficacy of iron preparations in abdominopelvic surgery has been highlighted recently 15 .
In light of this, the present RCT aimed to compare the efficacy of intravenous and oral iron in reducing allogeneic red blood cell transfusion requirement in patients undergoing colorectal cancer surgery. The primary outcome examined was differences in the mean volume of allogeneic red blood cell transfusion administered from preoperative recruitment to postoperative outpatient department review. Secondary endpoints included changes in haemoglobin and haematinic profiles.
Methods
Ethical approval for the IVICA (Intravenous Iron in Colorectal Cancer Associated Anaemia) trial was granted by the National Research and Ethics Service (Nottingham2, reference 11/EM/0237) before initiation, and the study was undertaken in line with the Declaration of Helsinki. The study was registered with both the Medicines and Healthcare Products Regulatory Agency, UK (reference 2011-002185-21) and Clinical Trials.Gov (NCT01701310).
The study was a multicentre RCT run across seven sites within the UK. Each site adhered to the principles of Good Clinical Practice, and the same transfusion practices. These were based on the Joint United Kingdom Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee guidelines for surgery, which state that transfusion should be considered if haemoglobin levels are below 8⋅0 g/dl, is usually indicated if the haemoglobin is below 7⋅0 g/dl, but that the decision to transfuse should be based on the clinical condition of the patient 16 .
Study population
All patients diagnosed with colorectal adenocarcinoma between May 2012 and June 2014 were screened for eligibility. The initial screening decision was made based on the most recent haemoglobin measurement available at diagnosis. This was tested either as the patient was referred to the outpatient department for investigation, following endoscopic evaluation of a suspected malignancy, or with analysis of renal function to ensure suitability for intravenous contrast during radiological staging assessment.
The haemoglobin inclusion criterion was defined as 1 g/dl below the sex-specific WHO definition 17 to ensure all included patients were anaemic at recruitment -below 11 g/dl for women and below 12 g/dl for men. Patients with metastatic disease, pre-existing haematological disease, renal failure and those currently undergoing chemotherapy were excluded to minimize the risk of inclusion of those with non-iron-deficient anaemia. Minors, prisoners, pregnant women and patients with contraindications to iron supplementation were also excluded. A full list of inclusion and exclusion criteria are outlined in Table S1 (supporting information).
Assignment
Recruited patients were randomized in a 1 : 1 fashion via a web-based system using variable block allocation, stratified by patient sex and age. The system was designed, set up and run by a unit independent of the study (Clinical Trials Unit, University of Nottingham). Treatment allocation was open-label as it was not possible to conceal the darkening of stool when ingesting oral iron.
Planned intervention
Intravenous iron was administered to the intervention arm. The preparation used was ferric carboxymaltose (Ferinject™; Vifor Pharma, Glattbrugg, Switzerland), which was diluted in 250 ml 0⋅9 per cent normal saline by an aseptic technique and infused over 15 min under the supervision of a clinician. The dose administered was calculated using patient bodyweight and inclusion haemoglobin value, as used in previous trials 18 and as advised in the summary of product characteristics ( Table 1) .
A maximum dose of 1000 mg was administered per week and a maximum of 2000 mg during the trial. If patients required two doses, the second dose was administered at least 7 days after the first. Patients in the control arm received oral iron, administered as ferrous sulphate 200 mg twice daily. Advice was given regarding ingestion without food and with liquid high in ascorbic acid to maximize enteric absorption 19 . This was continued until surgery.
Study visits
The initial recruitment visit occurred a minimum of 14 days before the planned date of surgery. At this visit, a full history, clinical examination and randomization were performed. The first dose of iron therapy was administered and any pre-existing oral iron supplements were discontinued at this point.
If a second dose of intravenous iron was required, patients would be reviewed again at least 1 week after the recruitment visit and the second dose administered. All patients were then reviewed around the time of operation: on the day of surgery before any intervention and on the second postoperative day. Patients were then followed up until their routine postoperative outpatient appointment approximately 2-3 months after discharge from hospital.
Completion of the trial was defined as attendance at the final outpatient visit. However, patients were also deemed to have completed the trial in the following circumstances. First, if a patient was recruited to the study and failed to undergo resectional surgery, the patient completed the trial at the time of surgery. All data obtained to this point were included in analysis. Alternatively, for patients who died before outpatient follow-up, or were lost to follow-up (for example owing to moving out of area), end of the trial was defined as the date of death or date of postoperative discharge from hospital.
Primary outcome assessment
At each study interaction, assessment was made regarding blood transfusion use in the preceding period. Volume and date of transfusion were recorded using hospital electronic transfusion databases and verified by reference to patient case-note records. All complications were recorded and graded using the Clavien-Dindo classification 20 , including adverse drug reactions.
Secondary outcome assessment
Blood tests were performed before initiation of treatment at the recruitment visit, including measurement of haemoglobin, ferritin and transferrin saturation (TSAT). These blood tests were repeated on the day of surgery before any clinical intervention.
Additional information
A measure of the volume of blood lost during the procedure was determined from recorded losses measured in suction devices and from the weight change of swabs used. This value was documented along with the volume and type of intravenous fluids infused during the procedure. All operative details were recorded. Tumour location, stage, size and grade were determined from the final histology report.
Sample size
A sample size estimation was performed to achieve a power of 90 per cent with an α level of P < 0⋅050. A clinically significant effect was defined as a 1-unit difference in mean transfused volume between groups. This was selected as it represents the minimum volume of an individual transfusion, and a dose-dependent increase in mortality and serious morbidity has been identified with each perioperative unit administered 8 . Using relevant published data (standard deviation in transfusion rate of 1⋅6 units) 21 , it was determined that 116 patients would be required, accounting for patient drop-out.
Statistical analysis
All analyses were by intention to treat. For variables with a non-normal distribution, paired data were compared using the Wilcoxon signed rank test, and independent data by means of Mann-Whitney U test. Normally distributed data were assessed with Student's t test. Two-tailed χ 2 test was used to analyse differences in categorical data. The level of statistical significance for all tests was P < 0⋅050. 
Results
A total of 116 patients were randomized, 61 to receive oral iron and 55 to intravenous iron (Fig. 1 ). There were no demonstrable differences between the two groups in demographic variables ( Table 2 ). Median duration of study iron treatment was 21 days in both groups (i.q.r. 15-33 days in oral and 15-34 days in intravenous group; P = 0⋅748), although 11 patients (6 oral, 5 intravenous; P = 0⋅891) failed to meet the desired 14-day treatment period. Of these, three had their date of operation moved owing to a change in clinical condition, and eight because an earlier date became available after recruitment to the study.
Median time to the outpatient appointment was comparable between groups, at 97 (i.q.r. 56-135) days for the oral group and 87 (53-145) days for the intravenous group (P = 0⋅849). The oral iron treatment protocol was adhered to by 50 (91 per cent) of the 55 patients who did not have the date of surgery moved. Two patients (3 per cent) reduced the dose owing to drug side-effects (dyspepsia and constipation), one of whom also had their operation date moved forward. Two patients increased the dose to three times daily on clinician request and two changed the drug oral formulation to ferrous fumarate after 14 days. No patient randomized to oral iron went on to receive intravenous iron.
In the intravenous iron group, 45 (82 per cent) of the 55 patients received two intravenous doses. The total dose administered was thus 2000 mg in 15 (27 per cent), 1500 mg in 30 (55 per cent) and 1000 mg in ten patients (18 per cent). It was calculated that four of those receiving 1000 mg needed a second dose, but two had their operation date moved forward and two were unable to attend the required appointment. Postinfusion (within 24 h) headache was the most frequent complication of intravenous iron administration, reported by three patients. Only one significant adverse drug reaction was experienced, a rash that required intervention in the form of oral antihistamine medication. Four patients had their operation cancelled on the day of surgery owing to deterioration in their clinical condition, one patient died during induction of anaesthesia, and the operation was abandoned at initial laparotomy in one patient as inoperable disease was found. Operative details for the 110 patients who underwent resectional surgery are summarized in Table 3 .
Outcome data
Two patients received a combined total of 3 units of blood before surgery, both in the oral iron group. Six patients in each group had a blood transfusion on the day of surgery (P = 0⋅894), with no difference in mean volume transfused (P = 0⋅863). From recruitment until the end of the study, there was no difference in mean transfused volume between the oral and intravenous groups (0⋅632 (95 per cent c.i. 0⋅258 to 1⋅006) and 0⋅698 (0⋅151 to 1⋅246) units respectively; P = 0⋅841) or number of patients transfused (14 versus 10; P = 0⋅470).
Haemoglobin levels at recruitment were comparable between groups, yet were significantly higher in the intravenous group at the time of surgery (Fig. 2) . This equated to a significantly greater median treatment rise in haemoglobin for intravenous iron (1⋅55 (i.q.r. 0⋅93-2⋅58) g/dl) compared with oral administration (0⋅50 (−0⋅13 to 1⋅33) g/dl; P < 0⋅001). At surgery, a significantly higher proportion of patients in the oral group than in the intravenous group remained anaemic: 55 of 61 (90 per cent) versus 41 of 55 (75 per cent) (P = 0⋅048). Thirty patients in the oral group required postoperative iron supplementation compared with only four in the intravenous group (P < 0⋅001).
Ferritin levels were significantly higher in the intravenous group at surgery (median 558 (i.q.r. 330-1085) μg/l versus 27⋅5 (17-51⋅5) μg/l in oral group; P < 0⋅001), despite parity in recruitment ferritin levels (P = 0⋅224). This same relationship was evident with TSAT levels at surgery (median 19 (16-29) and 9 (5-14) per cent respectively; P < 0⋅001), despite TSAT levels being significantly lower in the intravenous group at recruitment (P = 0⋅039).
Postoperative length of hospital stay was 6 days for both groups (i.q.r. 4-9 and 5-10 days for oral and intravenous groups respectively; P = 0⋅950). There were nine deaths in the entire cohort over the duration of the study, four in the oral group and five in the intravenous group (P = 0⋅872). Ninety-day mortality rates were similar (2 and 3 deaths respectively; P = 0⋅906). There was no difference in grade of complication severity between groups from recruitment to outpatients (P = 0⋅995) or in complication rate over the same period (P = 0⋅305). The same was true for grade (P = 0⋅083) and rate (P = 0⋅091) of infective complications.
Discussion
Patient blood management aims to improve outcome by minimization of allogeneic red blood transfusion use 1 , the requirement for which is linked directly to preoperative anaemia 22 . The primary aim of this prospective randomized study was to determine whether intravenous administration of iron would reduce blood transfusion as a consequence of more efficacious treatment of anaemia in a large cohort of patients undergoing elective surgery for colorectal cancer. Although the present results did indicate that intravenous iron was more effective in treating preoperative anaemia in this patient group, this did not translate into a significant difference in blood transfusion use.
It was also of interest that no differences were evident in postoperative outcomes. Severity of preoperative anaemia has been linked previously with direct increases in mortality, morbidity and length of stay following surgery (reviewed by Muñoz and colleagues 23 ). It would therefore be expected that the more efficacious treatment of anaemia with intravenous iron might confer greater benefits than oral iron on these outcomes measures. The non-inferiority of intravenous iron administration in this context must also be noted. The present study demonstrated that intravenous iron could be administered safely to this patient cohort, and did not identify any of the severe adverse reactions associated historically with older preparations 24 . Furthermore, intravenous administration of iron was not associated with an increase in infective complication rates, which has been identified previously as a potential limitation to its use 25 .
One key limitation of the study was that overall transfusion use was lower than anticipated, which may render the study vulnerable to type II error. Previous studies have identified perioperative transfusion rates in the order of 50 per cent among untreated anaemic patients with colorectal cancer 21 , with similar values for those treated with oral iron 26 . The smaller number in the present study may reflect a higher uptake of laparoscopic surgery than in previous trials, indicating the key role that blood loss has in the need for perioperative transfusion.
Although intravenous iron was demonstrated to be a superior treatment for iron deficiency here, it is possible that the duration of preoperative therapy was insufficient to allow this treatment to have maximal effect on haemoglobin levels, which could have influenced the use of blood transfusion. Preclinical 27 and clinical 18 studies have indicated that maximal intravenous iron utilization takes longer than the 21-day treatment period used in the present study. If intravenous iron could be administered earlier in clinical practice, for example as soon as anaemia is identified, a greater rise in haemoglobin level may become apparent with potential further reductions in blood transfusion. In contrast, it could be argued that the effect of oral iron in this study is the maximum that may be achieved in clinical practice. The adherence rate was higher than is generally expected and would be expected to decline with longer treatment periods 28 .
No overall benefit was seen with intravenous compared with oral iron in reducing allogeneic red blood cell transfusion. However, intravenous administration appeared more effective than the oral route in treating anaemia and iron deficiency in anaemic patients with colorectal cancer. This may not have had a clinical effect on transfusion use owing to the duration of study treatment. However, given the significant cost differences between these treatments and the simplicity of oral administration, further study may be required before intravenous iron is used as first-line treatment in this setting. 
